Zhejiang Cheng Yi Pharmaceutical Co., Ltd. (SHA:603811)

SHA:603811 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	744.84	712.31	669.61	653.25	693.45	757.43
Other Revenue	2.06	2.06	2.01	1.72	0.52	0.7
Revenue	746.9	714.37	671.63	654.97	693.96	758.13
Revenue Growth (YoY)	10.35%	6.36%	2.54%	-5.62%	-8.46%	11.29%
Cost of Revenue	237.53	225.17	248.45	217.8	208.98	206.41
Gross Profit	509.37	489.2	423.17	437.17	484.99	551.72
Selling, General & Admin	312.91	308.66	246.92	269.61	280.27	344.57
Research & Development	42.96	47.08	47.14	44.3	39.72	31.79
Other Operating Expenses	15.58	12.34	7.46	7.77	10.7	9.68
Operating Expenses	369.92	365.77	302.46	321.83	331.21	387.13
Operating Income	139.45	123.43	120.71	115.34	153.78	164.59
Interest Expense	-9.02	-11.09	-15.26	-9.13	-4.52	-4.96
Interest & Investment Income	44.45	46.28	67.12	49.08	31.87	24.36
Earnings From Equity Investments	-0.89	-	-	-	-	-
Currency Exchange Gain (Loss)	0.01	0.01	-0.17	3.45	5.36	-0.62
Other Non Operating Income (Expenses)	-0.33	-0.07	-0.31	-0.11	-0.99	-0.21
EBT Excluding Unusual Items	173.67	158.56	172.1	158.62	185.49	183.16
Impairment of Goodwill	-	-	-	-2.42	-2.92	-4.92
Gain (Loss) on Sale of Investments	-	-	-	-3.55	10.69	-
Gain (Loss) on Sale of Assets	68.99	69.17	-0	0.06	-0.45	0
Asset Writedown	-24.6	-24	-7.47	-0.41	-0.5	-3.21
Other Unusual Items	15.75	14.4	9.44	11.53	5.19	13.86
Pretax Income	233.81	218.13	174.06	163.84	197.5	188.89
Income Tax Expense	18.89	17.35	12.01	2.66	26.27	23.94
Earnings From Continuing Operations	214.92	200.79	162.05	161.18	171.23	164.95
Minority Interest in Earnings	-1.12	-0.09	0.85	0.4	-0.43	0.19
Net Income	213.81	200.7	162.9	161.58	170.8	165.14
Net Income to Common	213.81	200.7	162.9	161.58	170.8	165.14
Net Income Growth	37.20%	23.21%	0.81%	-5.39%	3.42%	25.69%
Shares Outstanding (Basic)	329	329	326	330	328	326
Shares Outstanding (Diluted)	329	329	326	330	328	326
Shares Change (YoY)	1.35%	0.99%	-1.20%	0.67%	0.59%	-0.09%
EPS (Basic)	0.65	0.61	0.50	0.49	0.52	0.51
EPS (Diluted)	0.65	0.61	0.50	0.49	0.52	0.51
EPS Growth	35.38%	22.00%	2.04%	-6.02%	2.82%	25.80%
Free Cash Flow	215.96	145.83	123.93	-86.92	9.38	34.13
Free Cash Flow Per Share	0.66	0.44	0.38	-0.26	0.03	0.10
Dividend Per Share	0.250	0.250	0.200	0.179	0.179	0.179
Dividend Growth	25.00%	25.00%	11.98%	-	-	22.50%
Gross Margin	68.20%	68.48%	63.01%	66.75%	69.89%	72.77%
Operating Margin	18.67%	17.28%	17.97%	17.61%	22.16%	21.71%
Profit Margin	28.63%	28.09%	24.25%	24.67%	24.61%	21.78%
Free Cash Flow Margin	28.91%	20.41%	18.45%	-13.27%	1.35%	4.50%
EBITDA	238.32	217.99	198.04	176.89	208.45	212.46
EBITDA Margin	31.91%	30.52%	29.49%	27.01%	30.04%	28.02%
D&A For EBITDA	98.87	94.56	77.32	61.55	54.67	47.87
EBIT	139.45	123.43	120.71	115.34	153.78	164.59
EBIT Margin	18.67%	17.28%	17.97%	17.61%	22.16%	21.71%
Effective Tax Rate	8.08%	7.95%	6.90%	1.62%	13.30%	12.68%
Revenue as Reported	746.9	714.37	671.63	654.97	693.96	758.13
Advertising Expenses	-	3.85	1.81	0.89	1.41	1.41

Updated Oct 28, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.